Summary Natural human interferon f, (fi-IFN) was tested during the early phase of in vitro infection with HTLV-I virus of human cord blood mononuclear cells (CBL), to evaluate whether its antiviral and immunomodulating effects might prevent spreading of infection in the host. ,B-IFN was found to reduce HTLV-I transmission and integration in CBL cultures. Moreover, ,B-IFN had no effect in preventing virus transmission and integration in K562 and a very limited effect in HL60 and Molt-4 human tumour lines, suggesting a cell-type specific mode of action.
Human T-cell leukaemia/lymphoma virus type I (HTLV-I), was the first human retrovirus to be associated with an aggressive form of adult T-cell leukaemia (ATL) (Gallo, 1985; Takatsuki et al., 1985) . HTLV-I is highly tropic for the CD4 + lymphocyte subset and integrates in the genome leading to transformation. The surface phenotype of ATL cells, as characterised by monoclonal antibodies, is CD3+, CD4+, CD8-, CD11- (Hattori et al., 1981) . ATL cells also express IL-2 receptors and class II HLA antigens (Waldmann et al., 1984) . However, HTLV-I transmission does not seem to be restricted to T lymphocytes, since B-cells (Longo et al., 1984; Tomita et al., 1985) , some non-lymphoid cell lines (Clapham et al., 1983) and primary endothelial cell cultures (Ho et al., 1984; Hoxie et al., 1984) can also be infected in vitro. Receptors for HTLV-I are indeed present on different types of cells from various species, although not all the receptor-positive cells are susceptible to stable infection (Sinangil et al., 1985) . The mechanisms of tissuespecific transformation mediated by HTLV-I are still unclear. It has been suggested that they are mediated by trans-acting transcriptional factor(s) of viral origin, that regulate(s) both HTLV promoter/enhancer sequences and activation of specific cellular genes controlling lymphocyte growth (Weiss, 1984; Haseltine et al., 1985) .
HTLV-I infection is accompanied by several alterations in immune function, including T-cell proliferation independently of IL-2 regulation (Popovic et al., 1983a,b) and indiscriminant helper function (Popovic et al., 1984; Volkam et al., 1985; Yarchoan et al., 1986) . Since the specific target cell of HTLV-I is an immunocompetent cell, infection of T lymphocytes would result in a severe dysfunction of the immune system, which in turn could fail to control virus infection. Therefore, it is reasonable to hypothesize that immunosurveillance mechanisms play a significant role in controlling the early stages of HTLV-I transmission and preventing spreading of infection. In this respect, immunomodulating agents influence the rate and extent of target cell infection. They could protect from a massive horizontal transmission of HTLV-I and/or prevent the selection of the transformed clone(s).
Interferons (IFNs) are potent antiviral and antitumour agents (Lengyel, 1982) . oc and f3-IFN have been tested in clinical trials for therapy of virus-induced diseases (Scott, 1983) . The effects of IFNs may be amplified by their known ability to modulate the immune system by regulating macrophage and lymphocyte functions. In view of this possibility, the effects of P-IFN on early stages of in vitro infection with HTLV-I have been tested. The present results show that f-IFN could effectively reduce both HTLV-I transmission and integration in human cord blood lymphocytes (CBL). This effect appeared to be cell typespecific and could be due, at least in part, to boosting of the immune function of recipient CBL.
Materials and methods

Cell cultures and infection
Human mononuclear cells were collected from heparinized neonatal umbilical cord blood (CBL) on Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) gradients (1.077 g cm-3) (B0yum, 1968) , seeded in 24-well plates or 25 cm2 flasks (Falcon, Oxnard, USA) at a density of 0.5-1 x 106 ml1 and incubated at 37°C in humidified air containing 5% CO2. Human tumour lines were grown in 25 cm2 flasks (Falcon) and diluted serially every 2 days. The culture medium was RPMI 1640 (Gibco, Grand Island, USA), plus 20% heatinactivated foetal calf serum (FCS) (Gibco), 2mM glutamine (Gibco) and 100 U ml-penicillin/streptomycin. For CBL cultures, the medium was supplemented with 5% purified IL-2 (Cellular Products, Buffalo, USA) to guarantee the survival of lymphocytes (Morgan et al., 1976) . In longterm CBL cultures, the medium was renewed every week and fresh IL-2 added. Infection was achieved by coculturing CBL or recipient tumour lines with an HTLV-I producer line, MT-2 (Miyoshi et al., 1981; Yoshida et al., 1982) , at a ratio of 5:1. MT-2 cells were lethally irradiated (120Gy, Cesium Gamma Cell 1000, Canada Atomic Energy Ltd., Canada) before co-culturing. The human cell lines used as recipient cells were the erythroleukaemia K562 (Lozzio & Lozzio, Calculation of lytic units Dose-response curves were obtained by plotting the percentage of specific 51Cr release and the effector:target ratios. The best fit curve for this function was found to be logarithmic in accordance with previous reports (Thorn & Henney, 1976) . A lytic unit n% (LUn) was defined as the number of effector cells, extrapolated from the dose-response curve, which were required to achieve n% specific target cell lysis. LUn 10-6 effector cells was calculated by dividing 106 by the number of lymphocytes corresponding to 1 LUn.
Assay for CBL proliferation in mixed lymphocyte/tumour culture CBL proliferation during coculture with MT-2 infecting cells was tested either in whole CBL cultures or at an optimal macrophage: lymphocyte ratio of 1: 20, to enhance the antigen presenting function of macrophages (M0 In vitro infection of human tumour cells line K562, Molt-4 and HL-60 cells were infected by coculturing with MT-2 cells as for CBL cultures. Viral p19 was assayed by indirect immunofluorescence 5 days p.i., since HTLV-I was cytopathic for recipient cells and their viability on day 5 was generally reduced to 40-50%, approaching total cell death after 10 days.
All 3 cell lines were susceptible to HTLV-I infection and 10-20% cells became pl9+ after 5 days (data not shown).
Pretreatment of the recipient line or cotreatment with fl-IFN had no effect on HTLV-I infection, with the exception of one out of two experiments with HL60, in which monoclonal antibodies to various surface markers (Table II) Cell-mediated cytotoxicity offreshly isolated or HTLV-I infected CBL Freshly isolated CBL showed low natural cell-mediated cytotoxicity against K562 target cells and were essentially non cytotoxic for MT-2 blasts (Table III) . However K562 and MT-2 targets were efficiently lysed by fl-IFN pretreated CBL (Table III) . Cell-mediated cytotoxicity of virus-exposed CBL (hereafter referred to as 'infected CBL') was drastically reduced as compared with non-infected controls (Table IV) . On day 7, infected CBL were poorly cytotoxic not only for a typical natural killer target such as K562, but also for the same infecting and sensitizing allogeneic MT-2 cells, as for an EBV-transformed tumour cell line (X303, see Table IV footnote), both the last two lines expressing class I and II HLA antigens.
IL-2 in the culture medium could boost only the killing capacity of uninfected CBL against K562 or MT-2 cells, whereas infected CBL were totally refractory to interleukin stimulation (Table IV) . The poor killing capacity of CBL against MT-2 cells was not due to the unfavourable ratio of CBL (responder cells) to MT-2 (sensitizer cells) for eliciting cytotoxic T lymphocytes (CTL). In fact, CBL infected (and sensitized) with MT-2 at the optimal infective ratio (5:1) or at the usual responder/sensitizer cell ratio (40:1) for CTL generation, were equally unable to kill MT-2 cells (Table   IV) .
Pretreatment of CBL with fJ-IFN greatly enhanced the cytotoxic capacity of infected CBL when tested against K562 or MT-2 cells and this enhancement was detectable up to 4wks of coculture (Table IV) .
CBL proliferation in mixed culture with MT-2 tumour cells
Proliferation of mononuclear cells in mixed lymphocyte/ tumour cell culture was evaluated shortly after infection by 3H-thymidine incorporation in blast cells. Although most of dividing cells are activated lymphocytes, some dividing cells can also be monocytes (Van Furth, 1982) triggered by coculture with MT-2. Thymidine incorporation by normal CBL was marginal, unless IL-2 was present in the medium.
In this case f1-IFN reduced CBL proliferation by 50% (data not shown). In the presence of IL-2 in the medium, infected CBL incorporated 10-15 fold less thymidine than non-infected controls (day 4-6 p.i.) and f-IFN had no effect on this low incorporation rate (data not shown). Thymidine incorporation was measured in CBL cocultured with MT-2 cells at the optimal M0: Ly ratio for antigenpresenting function (1:20). Data from a representative experiment summarized in Table V show that: (a) challenging with MT-2 cells reduced the IL-2-dependent thymidine incorporation of M0 + Ly much less than that of whole CBL, or Ly alone; (b) the incorporation rate regained the control levels when the cells were pretreated or cotreated with fJ-IFN at 1000 U ml -1. In the same experiment, the Sample CBL were pretreated overnight with 100 or 1000 U ml ,B-IFN.
Cytotoxicity is expressed as lytic units (Lu1o 10-6 CBL) calculated on the basis of the geometric mean + s.e. Probability (P) was calculated according to regression test analysis comparing NK activity between control CBL and IFNtreated CBL.
appearance of p19 positive cells in cocultured CBL was delayed and M0 showed a protective effect on Ly infection (Figure 1 ). ,B-IFN further reduced the percentage of pl9+ cells of this culture (Figure 1 ).
Discussion
Human peripheral, bone marrow and cord blood lymphocytes can be transformed efficiently in vitro by cocultivation with lethally irradiated allogeneic (Miyoshi et al., 1981; Merl et al., 1984; Markham et al., 1984) or autologous (Akagi et al., 1985) HTLV-I positive cell lines. Immature cells (cord blood or bone marrow lymphocytes) are easily infected in vitro in comparison with the peripheral blood lymphocytes of adult donors (Graziani et al., 1987) .
This might also occur in vivo, since bone marrow lymphocytes may represent a more permissive target for HTLV-I in adults, as is the case of instances of mother to foetus transmission. HTLV-I probe (dot blots) showed a reduction of virus integration in IFN-treated CBL at 2 weeks p.i. At 4 weeks p.i., provirus integrated DNA was still low in IFN-cotreated CBL cultures, whereas in IFN-pretreated CBL it became closer to untreated CBL. It is reasonable to suggest that, after 4 weeks, cells which had effectively integrated HTLV-I provirus expanded independently of early IFN treatment, although not all cells expressed p19 antigen (c.f. Table I ). On the other hand, HTLV-I integration was also clearly reduced by IFN in cases in which the percentage of p19+ CBL was only slightly affected (data not shown).
These data suggest that transmission and integration of HTLV-I might be independently affected by fl-IFN. In a murine sarcoma virus model, IFN was found to delay viral DNA synthesis and its transport to the nucleus and, most of all, to greatly reduce viral DNA integration by inhibiting the accumulation of supercoiled viral DNA (a precursor to integrated provirus) in the nucleus (Huleihel & Aboud, 1983) . fl-IFN was also shown to inhibit stabilisation and/or integration of exogenous oncogene sequences in the recipient cells, with an apparent effect on gene expression that reduced stable transformation by oncogenes (Perucho & Esteban, 1985 (Hattori et al., 1981; Waldmann et al., 1984 (Nair et al., 1985) . Moreover, the poor killing capacity of infected CBL against K562 target cells was still enhanced by IFN during the culture period. This effect of IFN should be underlined considering that a decline of natural killer activity of lymphocytes was found in HTLV-I infected patients (De Vecchis et al., 1985) and that large granular lymphocytes (LGL) with NK activity have recently been shown to afford T-cell protection from infection of PBL by HTLV-I (Ruscetti et al., 1986; Macchi et al., 1987) . The fact that few CBL were positive for Leu7 phenotype marker of LGL (Table III) does not rule out their role against HTLV-I infection, since the phenotype of LGL differs in CBL compared with PBL and may also be Leu7 (Vitiello et al., 1984) .
A more efficient antisensitizer cytotoxic response might also be relevant in the very early phase of infection to reduce spreading of infected cells. HTLV-I infection of CBL causes a severe reduction of their cytotoxic capacity, independent of the infecting ratio (CBL: MT-2 = 5:1 or 40:1). Under these conditions, the ability of f-IFN to boost the whole killing capacity of CBL (against both K562 and MT-2 cells) during long-term culture could conceivably play a role in counteracting in vitro transmission of HTLV-I. One single treatment with 1000 U ml-1 of IFN just before infection was highly effective. The possibility that IFN would prevent HTLV-I infection via suppressive effects on target cell proliferation appears to be ruled out by the fact that coculture of CBL with HTLV-I producer MT-2 cells reduced the 3H-thymidine incorporation of whole CBL to very low levels that were not further affected by IFN treatment (data not shown). In these conditions, however, the suppressive role of M0 might be prevalent (Holt et al., 1981; Veit, 1982) . By repeating the test at the optimal M0:Ly ratio of 1:20,.it was found that blastogenesis was much less reduced during coculturing, compared with the level in whole CBL cultures and fl-IFN could restore proliferation levels comparable to those of non-infected controls.
In this MT-2/CBL allogeneic system, the level of 3H-thymidine incorporation in mononuclear blasts is a result of activation of the immune response. M0 are supposed to contribute in part to the amount of 3H-thymidine incorporation, since their proportion is highly increased within 4 days p.i., as shown by determination of the M3 phenotype. In addition, the optimal M0/Ly ratio for antigenpresentation resulted in highly effective protection against HTLV-I transmission, since the relative number of pl9+ cells remained low up to 5 weeks of culture and fl-IFN further increased this protective effect. Hence, efficient macrophage function together with high killing capacity of effector cells are likely to protect against HTLV-I infection in vitro. The boosting effect of IFN was demonstrated on the overall cytotoxic capacity of CBL and on their proliferation in response to infecting allogeneic cells. Thus, JJ-IFN may reduce the severe depression of immune function that follows HTLV-I infection, in addition to direct cell-type specific protection from integration of HTLV-I provirus. These combined effects of fl-IFN can afford a good protection from HTLV-I infection in vitro and suggest a role for fJ-IFN in the prophylaxis of HTLV-I infection in endemic areas with a high incidicidence of serum-positive subjects. Moreover, the present study would encourage extension of immunomodulating approaches for the management of retroviral infections in human pathology.
